Log in

NASDAQ:OMER - Omeros Stock Price, Forecast & News

$13.12
+0.48 (+3.80 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$12.55
Now: $13.12
$13.24
50-Day Range
$12.61
MA: $13.47
$15.00
52-Week Range
$12.31
Now: $13.12
$20.92
Volume310,097 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:OMER
CUSIP68214310
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees236
Next Earnings Date3/6/2020 (Estimated)
OptionableOptionable

Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.


Omeros (NASDAQ:OMER) Frequently Asked Questions

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) posted its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.08. The biopharmaceutical company earned $29.86 million during the quarter, compared to the consensus estimate of $27.19 million. The company's revenue was up 547.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.81) earnings per share. View Omeros' Earnings History.

When is Omeros' next earnings date?

Omeros is scheduled to release their next quarterly earnings announcement on Friday, March 6th 2020. View Earnings Estimates for Omeros.

What price target have analysts set for OMER?

5 equities research analysts have issued 1-year price objectives for Omeros' stock. Their forecasts range from $18.00 to $34.00. On average, they expect Omeros' stock price to reach $25.75 in the next year. This suggests a possible upside of 96.3% from the stock's current price. View Analyst Price Targets for Omeros.

What is the consensus analysts' recommendation for Omeros?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omeros.

Has Omeros been receiving favorable news coverage?

Press coverage about OMER stock has trended negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Omeros earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Omeros.

Who are some of Omeros' key competitors?

What other stocks do shareholders of Omeros own?

Who are Omeros' key executives?

Omeros' management team includes the folowing people:
  • Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 60)
  • Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 61)
  • Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 59)
  • Dr. Pamela Pierce Palmer, Co-Founder (Age 56)
  • Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 62)

Who are Omeros' major shareholders?

Omeros' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Ingalls & Snyder LLC (9.35%), State Street Corp (2.23%), Stifel Financial Corp (1.72%), UBS Group AG (1.01%), Charles Schwab Investment Management Inc. (0.61%) and Credit Suisse AG (0.43%). Company insiders that own Omeros stock include Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros.

Which major investors are selling Omeros stock?

OMER stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, PNC Financial Services Group Inc., Chicago Equity Partners LLC, Bank of America Corp DE, New York State Common Retirement Fund, California Public Employees Retirement System, First Interstate Bank and Goldman Sachs Group Inc.. View Insider Buying and Selling for Omeros.

Which major investors are buying Omeros stock?

OMER stock was purchased by a variety of institutional investors in the last quarter, including Monashee Investment Management LLC, Stifel Financial Corp, Jacobs Levy Equity Management Inc., UBS Group AG, State Street Corp, Charles Schwab Investment Management Inc., Capital Impact Advisors LLC and Alpine Global Management LLC. View Insider Buying and Selling for Omeros.

How do I buy shares of Omeros?

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $13.12.


MarketBeat Community Rating for Omeros (NASDAQ OMER)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  698 (Vote Outperform)
Underperform Votes:  464 (Vote Underperform)
Total Votes:  1,162
MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe OMER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: Penny Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel